Eosinophilic solid and cystic renal cell carcinoma (ESC RCC) has been recently described as a unique and indolent renal neoplasm, found in female patients with and without tuberous sclerosis complex. Although ESC RCC has a distinct morphology and frequent CK20 reactivity, its molecular karyotype has been previously studied only in few cases. We identified 19 ESC RCC from multiple institutions; all patients were female individuals without clinical features of tuberous sclerosis complex. Molecular karyotyping was performed in 13 cases (12 with informative result). The median age was 55 years (range: 32 to 79 y). The tumors were yellow-gray with a median size of 31 mm (range: 12 to 135 mm) and showed solid and cystic gross appearance. All tumors demonstrated typical microscopic features with solid areas admixed with variably sized macrocysts and microcysts. The cells showed eosinophilic cytoplasm with granular cytoplasmic stippling and round-to-oval nuclei. CK20 was positive in 14/19 (74%) cases. Stage pT1 was found in 17/19 (89%) patients (pT1a in 12, pT1b in 5); 1 patient each had pT2a and pT3a. A total of 15/16 patients with available follow-up were alive and without evidence of disease progression, after 1 to 169 months (median: 44 mo; mean: 49.6 mo); 3 died of other causes. The most common copy number gains were 16p13.3-16q23.1 (33% to 67%), 7p21.2-7q36.2 (42% to 50%), 13q14.2 (33%), and 19p12 (33%). The most common copy number losses included Xp11.21 (42%) and 22q11.23 (33%). Loss of heterozygosity was most frequently found at 16p11.2-11.1 (75%), Xq11.1-13.1 (75%), Xq13.1-21.1 (33%), 11p11.2-11.11 (33%), 9q21.1-22.2 (33%), and 9q33.1 (33%). ESC RCC demonstrates common molecular karyotype alterations, which further support its distinct nature.

*Calgary Laboratory Services and University of Calgary ***Division of Urology University of Calgary Calgary AB Canada †Charles University Pilsen Czech Republic ‡Cruces University Hospital BioCruces Institute University of the Basque Country Barakaldo Bizkaia Spain §Carregi Hospital Florence Italy ∥Pitié Salpêtrière Hospital ¶Hopital Cochin Paris ‡‡Université Lille Lille France Emory University School of Medicine Atlanta GA **New York University Medical Center New York NY ††University of Arkansas for Medical Sciences Little Rock AR §§Barts Cancer Institute Queen Mary University of London London United Kingdom ∥∥AC Camargo Cancer Center Sao Paulo Brazil ¶¶Diagnostico Srl Lab Pathology Montevideo Uruguay Federal University of Bahia Faculty of Medicine of Bahia Salvador Brazil †††Royal North Shore Hospital University of Sydney Sydney NSW Australia ‡‡‡Robert J Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic Cleveland OH

References provided by Crossref.org

Acceptance of emerging renal oncocytic neoplasms: a survey of urologic pathologists

TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background

New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia

Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia

Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer

"High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases